Inotuzumab Ozogamicin (CMC-544)

DRUG4 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

LymphomaLymphoma, B-Cell

Phase 1

Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

CompletedNCT00717925

Wyeth is now a wholly owned subsidiary of PfizerLymphoma, B-Cell

Start: 2007-03-31End: 2008-07-31Updated: 2015-12-09

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

CompletedNCT00724971

PfizerLymphoma, B-Cell

Start: 2008-07-04End: 2010-03-10Updated: 2019-03-15

Phase 2

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

CompletedNCT00867087

PfizerLymphoma, B-Cell

Start: 2009-06-08End: 2012-10-31Updated: 2017-12-05

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

CompletedNCT00868608

Start: 2009-07-30End: 2013-06-27Updated: 2017-10-31

Related Papers

Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modelling

British Journal of Clinical Pharmacology2018-12-0814 citations

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

2012-03-2050 citations

Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.

2010-04-2344 citations